C. Ola Landgren, M.D., Ph.D.
Medical Oncology Branch and Affiliates
Head, Multiple Myeloma Section
Senior Investigator
National Cancer Institute
9000 Rockville Pike
Building 10, Room 13N240
Bethesda, MD 20892
Phone: 301-496-0670
Fax: 301-402-0172
landgreo@mail.nih.gov
Dr. Landgren received his M.D. in 1995 from the Karolinska Institute in Stockholm, Sweden. Following clinical training as a hematology/internal medicine specialist physician, he earned a Ph.D. with a focus on diagnostics and prognostics in Hodgkin lymphoma in 2002 at Karolinska Institute. He then served as an attending physician at Karolinska and conducted clinical research on lymphoproliferative malignancies and related precursors. He came to the National Cancer Institute’s (NCI) Division of Cancer Epidemiology and Genetics (DCEG) in 2004, where he served as an Investigator before he joined the Medical Oncology Branch.
Dr. Landgren's major research interests are in the treatment, causation, diagnostics and prognostics, and natural history of multiple myeloma and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). He also studies related hematologic malignancies and their precursor states, including chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis (MBL); Waldenstrom’s macroglobulinemia, and IgM MGUS, as well as myeloproliferative neoplasms. His research focuses on treatment-, host-, disease-, and immune-related factors in the pathway from precursor to full-blown malignancy and their relation to outcome.
Dr. Landgren's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with MGUS, smoldering myeloma, and multiple myeloma. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.
Head, Multiple Myeloma Section
Senior Investigator
National Cancer Institute
9000 Rockville Pike
Building 10, Room 13N240
Bethesda, MD 20892
Phone: 301-496-0670
Fax: 301-402-0172
landgreo@mail.nih.gov
Dr. Landgren received his M.D. in 1995 from the Karolinska Institute in Stockholm, Sweden. Following clinical training as a hematology/internal medicine specialist physician, he earned a Ph.D. with a focus on diagnostics and prognostics in Hodgkin lymphoma in 2002 at Karolinska Institute. He then served as an attending physician at Karolinska and conducted clinical research on lymphoproliferative malignancies and related precursors. He came to the National Cancer Institute’s (NCI) Division of Cancer Epidemiology and Genetics (DCEG) in 2004, where he served as an Investigator before he joined the Medical Oncology Branch.
Dr. Landgren's major research interests are in the treatment, causation, diagnostics and prognostics, and natural history of multiple myeloma and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). He also studies related hematologic malignancies and their precursor states, including chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis (MBL); Waldenstrom’s macroglobulinemia, and IgM MGUS, as well as myeloproliferative neoplasms. His research focuses on treatment-, host-, disease-, and immune-related factors in the pathway from precursor to full-blown malignancy and their relation to outcome.
Dr. Landgren's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with MGUS, smoldering myeloma, and multiple myeloma. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.
Videocast/Podcast Details:The quality of these videocasts is dependent on the speed of your Internet connection. Many videocasts are streamed directly to your computer by software on the NIH VideoCasting Web site. Others require that you have a standalone player installed on your computer to handle the streaming. If you do not have a standalone player installed or if you are having problems viewing the videocast, please visit http://videocast.nih.gov/faq/.
| CC Grand Rounds: (1) Therapeutic Gene Delivery: Using
Hematopoietic Stem Cells in Sickle Cell Disease (2) Multiple Myeloma and
Its Precurser (MGUS): Looking into the Future Speaker(s): John F. Tisdale, M.D., Senior Investigator, Molecular and Clinical Hematology Branch, NHLBI Ola Landgren, M.D., Ph.D., Investigator, Medical Oncology Branch, Center for Cancer Research, NCI April 16, 2010 60 minutes http://videocast.nih.gov/launch.asp?15720 |
| Eradicating Multiple Myeloma Speaker(s): C. Ola Landgren, M.D., Ph.D., Head, Multiple Myeloma Section, Medical Oncology Branch and Affiliates, NCI September 15, 2010 3 minutes, 32 seconds http://bethesdatrials.cancer.gov/rss/videocastdetail.aspx?webcastid=9 |
| NIH Director's Seminar Series: Multiple Myeloma and its Precursor Disease: the Future is Already Here Speaker(s): C. Ola Landgren, M.D., Ph.D. Head, Multiple Myeloma Section, Medical Oncology Branch and Affiliates, NCI April 20, 2012 50 minutes http://videocast.nih.gov/Summary.asp?File=17227 |
DANGEROUS MEDICAL EUPHEMISMS:
ReplyDelete"MGUS" no longer "benign".
"smoldering myeloma" = active plasma cell cancer
Similar to "adrenal incidentaloma", often anindication of CONN syndrome.